Finanzen von Artelo Biosciences, Inc (ARTL)ARTLArtelo Biosciences, Inc

Evaluating the bottom line, Artelo Biosciences, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -705.71%, provide a clear picture of how effectively ARTL converts its operational activities into shareholder value.

In the context of the broader market, ARTL competes directly with industry leaders such as JAGX and MTNB. With a market capitalization of $1.15M, it holds a significant position in the sector. When comparing efficiency, ARTL's gross margin of N/A stands against JAGX's 15.84% and MTNB's N/A. Such benchmarking helps identify whether Artelo Biosciences, Inc is trading at a premium or discount relative to its financial performance.

Artelo Biosciences has reported negative net income consistently, with Q1 2026 showing a loss of -$2,958,000. The company's EPS has been negative, with the latest reported at -0.89. The current ratio has improved to 3.00 in Q2 2026, indicating better liquidity, but overall financial health remains weak.